Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NAVB | Navidea Biopharmaceuticals, Inc.

Index- P/E- EPS (ttm)-0.44 Insider Own26.30% Shs Outstand99.83M Perf Week-20.92%
Market Cap10.08M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float65.74M Perf Month5.92%
Income-14.30M PEG- EPS next Q- Inst Own4.70% Short Float / Ratio3.83% / 0.44 Perf Quarter-3.85%
Sales0.01M P/S1240.15 EPS this Y-39.30% Inst Trans0.10% Short Interest2.52M Perf Half Y-69.87%
Book/sh-0.02 P/B- EPS next Y- ROA-129.70% Target Price- Perf Year-63.50%
Cash/sh0.06 P/C1.65 EPS next 5Y- ROE113.20% 52W Range0.06 - 0.35 Perf YTD-54.81%
Dividend- P/FCF- EPS past 5Y20.00% ROI- 52W High-72.89% Beta1.48
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin- 52W Low51.60% ATR0.02
Employees11 Current Ratio0.80 Sales Q/Q- Oper. Margin- RSI (14)50.28 Volatility20.35% 16.99%
OptionableYes Debt/Eq- EPS Q/Q66.50% Profit Margin- Rel Volume0.93 Prev Close0.10
ShortableYes LT Debt/Eq- EarningsMar 21 AMC Payout- Avg Volume5.74M Price0.09
Recom2.00 SMA202.25% SMA504.21% SMA200-50.51% Volume5,309,929 Change-5.01%
Date Action Analyst Rating Change Price Target Change
Nov-13-13Reiterated Aegis Capital Hold $3 → $2
Nov-07-13Reiterated Ladenburg Thalmann Buy $7.50 → $3
Jan-24-13Initiated Burrill Institutional Research Mkt Outperform $5
Jan-22-13Initiated Aegis Capital Hold $3
Sep-11-12Reiterated WBB Securities Strong Buy $9 → $7
Sep-11-12Reiterated Rodman & Renshaw Mkt Outperform $7 → $6
Sep-11-12Reiterated Ladenburg Thalmann Buy $6.25 → $7.50
Aug-10-23 09:29AM
Aug-01-23 06:45AM
Jul-31-23 09:32AM
Jul-28-23 08:23PM
Jul-27-23 05:20PM
05:09PM Loading…
Jul-13-23 05:09PM
Jun-30-23 09:16AM
Jun-16-23 04:54PM
Jun-07-23 04:00PM
Jun-02-23 05:54PM
Jun-01-23 05:53PM
May-22-23 06:30PM
May-11-23 05:35PM
May-08-23 04:12PM
05:14PM Loading…
Apr-27-23 05:14PM
Apr-13-23 04:50PM
Mar-30-23 05:02PM
Mar-24-23 07:36AM
Mar-22-23 08:28AM
Mar-21-23 04:01PM
Mar-15-23 07:30AM
Jan-03-23 08:30AM
Dec-28-22 09:59AM
Nov-30-22 08:04PM
Nov-28-22 08:30AM
Nov-14-22 05:23PM
Nov-07-22 04:05PM
Nov-04-22 07:30AM
04:30PM Loading…
Oct-05-22 04:30PM
Sep-30-22 08:30AM
Sep-15-22 08:30AM
Sep-08-22 04:00PM
Sep-01-22 08:30AM
Aug-30-22 09:30AM
Aug-25-22 09:16AM
Aug-18-22 08:26AM
Aug-15-22 08:30AM
Aug-04-22 07:30AM
Aug-01-22 04:30PM
Jul-25-22 07:30AM
Jul-20-22 08:57AM
Jul-05-22 08:00AM
May-24-22 08:30AM
May-23-22 07:30AM
May-12-22 07:30AM
May-05-22 07:30AM
Apr-20-22 06:58AM
Apr-18-22 04:01PM
Apr-12-22 04:05PM
Apr-07-22 07:30AM
Mar-23-22 03:44PM
Mar-16-22 07:30AM
Feb-07-22 07:30AM
Feb-03-22 04:01PM
Dec-16-21 04:01PM
Dec-15-21 04:02PM
Dec-13-21 07:30AM
Dec-09-21 04:01PM
Nov-04-21 03:01PM
Nov-03-21 04:01PM
Oct-26-21 05:22PM
Oct-14-21 07:30AM
Sep-27-21 07:30AM
Sep-20-21 09:07AM
Sep-17-21 07:30AM
Aug-11-21 05:15PM
Aug-04-21 07:30AM
Jul-19-21 07:30AM
Jul-15-21 07:30AM
Jun-24-21 07:00AM
Jun-14-21 07:32PM
May-19-21 07:30AM
May-11-21 04:01PM
May-05-21 08:00AM
May-04-21 07:30AM
Apr-15-21 07:30AM
Mar-24-21 04:21PM
Mar-17-21 07:30AM
Mar-02-21 04:01PM
Feb-09-21 08:09AM
Feb-08-21 04:05PM
Jan-07-21 07:30AM
Dec-28-20 07:30AM
Dec-08-20 09:51AM
Nov-26-20 06:34PM
Nov-12-20 04:02PM
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.